© Copyright 2026, All Rights Reserved
Precision-guided peptide therapeutics for solid tumors and beyond
Target Nectin-4 expressing tumors with BTC conjugates; Treat EphA2-positive cancers with BTC conjugates; Activate CD137 in tumor microenvironment via Bicycle TICA®; Deliver radiopharmaceuticals using BRC™ technology; Develop therapies for anti-infective, cardiovascular, and CNS diseases through partnerships
Clinical-stage programs in active trials; Focus on undruggable targets like EphA2; Partnerships with academic and pharma leaders; Technology based on Nobel Prize-winning science; Headquartered in Cambridge, UK with US operations in Cambridge, MA